It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Sygnature Discovery provides in vitro permeability assays that predict absorption, distribution, and CNS exposure, helping you make confident decision early in development. Our models, including PAMPA, MDCK, and Caco-2, deliver translationally relevant data that guide compound selection and optimization.
Permeability is a critical determinant of oral drug absorption and systemic distribution. Our in vitro models such as PAMPA and cell-based monolayers (Caco-2, MDCK -MDR1/BCRP), enable mechanistic evaluation of passive diffusion and transporter-mediated movement. These systems allow bidirectional transport assessment and express key human efflux transporters, including P-glycoprotein (MDR1) and BCRP, which significantly influence drug disposition.
Characterizing compound interactions with these transporters supports accurate prediction of in vivo pharmacokinetics and informs potential drug-drug interaction risks. These insights strengthen pharmacokinetic modeling, CNS drug design, and strategic decision-making across discovery programs.
Permeability Expertise
Caco-2 Permeability
Caco-2 cells, derived from human colorectal adenocarcinoma, differentiate into polarized monolayers resembling small intestinal enterocytes with apical microvilli and tight junctions. This human-derived model is widely used to investigate passive and active transport mechanisms, providing valuable insights into oral absorption and CNS penetration potential for new chemical entities.
MDCK cells, derived from canine kidney epithelium, form polarized monolayers with tight junctions suitable for permeability studies. Genetically modified MDCK variants overexpress human efflux transporters such as P-glycoprotein (MDR1) and BCRP, creating robust in vitro platforms for evaluating drug permeability, efflux liability, and CNS penetration potential. These models also help assess oral absorption and identify transporter-mediated drug-drug interaction risks.
The parallel artificial membrane permeability assay (PAMPA) is a high throughput in vitro model for predicting passive transcellular permeability independent of active transport processes. Sygnature Discovery uses the Corning® BioCoatTM PAMPA system, featuring a lipid/oil/lipid tri layer membrane that mimics biological barriers. PAMPA demonstrates strong correlation with cell-based permeability assays and known human absorption profiles for passively permeable compounds, making it a valuable tool in early drug development.
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Integrated solid form and formulation strategies reduce risk, improve stability and solubility, and accelerate progression from candidate selection to clinic.
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
